Valneva Wins "Fastest Growing Listed Company" Tech 50 Award for France by
Deloitte
LYON, France, Nov. 24, 2016 (GLOBE NEWSWIRE) -- Valneva SE ("Valneva" or "the Company"), a fully integrated,
commercial stage biotech company focused on developing innovative life-saving vaccines, today announced that it has won the
"Fastest Growing Listed Company" Award for France in the 2016 Deloitte In Extenso Technology Fast 50(TM) ranking. Valneva also
ranked 43 out of 500 companies in Deloitte's 2016 Technology Fast 500(TM) EMEA.
The Technology Fast 50 and Fast 500 initiatives reward the fastest growing technology, media,
telecommunications, life sciences and energy tech companies - both public and private - in France and the EMEA region. Award
winners are selected for demonstrating innovation, leadership, and rapid revenue growth over their last four years of
operations.
Laurent Halfon, Deloitte Partner and country manager of the Technology Fast 50 program in
France, commented, "The Technology Fast 50 ranking promotes companies like Valneva which reflect the incredible drive for
innovation and added value creation of French entrepreneurs. Already in its 16th edition, the Technology Fast 50 France ranking has
become a true reference for French and international investors. We are proud to see Valneva among the winners for 2016."
Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, added, "This
award underpins the underlying rationale of Valneva's strategy focused on growing revenues through a combination of organic and
strategic growth while continuing to invest in promising Research & Development programs and activities."
Following a strong business performance in the first nine months of 2016, Valneva recently increased its
financial guidance and expects revenues between €95 and €100 million in 2016 and an EBITDA profit of €1-5 million. Valneva will
continue to build commercial and R&D value in the coming years and expects to grow its revenues to approximately €250 million
by 2020.
About Deloitte
Deloitte refers to Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network
of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed
description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms. In France, Deloitte SAS is the member
firm of Deloitte Touche Tohmatsu Limited, and professional services are provided by its subsidiaries and affiliates.
Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning
multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class
capabilities and high-quality service to clients, delivering the insights they need to address their most complex business
challenges. Deloitte's approximately 244,000 professionals are committed to becoming the standard of excellence.
About Deloitte Technology Fast 500 TM EMEA
The Deloitte Technology Fast 500EMEA programme is the region's most objective EMEA region industry-ranking to
focus on the technology field, recognising tewchnology companies that have achieved the fastest rates of revenue growth in Europe,
the Middle East, and Africa.
Combining technology innovation, entrepreneurship and rapid growth, Fast 500 companies span a variety of
industry sectors, and are leaders in hardware, software, communications, media, life sciences and clean technology.
The programme is supported by the Deloitte Technology Fast 50 initiatives, which rank high growth technology
companies by location or specifically defined geographic area and is run by the Deloitte Touche Tohmatsu Limited's Technology. More
information on the programme and winners is available on www.deloitte.com/fast500emea
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and
commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative
medicine.
The Company seeks financial returns through focused R&D investments in promising product candidates and
growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva's portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT®
indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some
countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against
Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the
Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms
(EB66® vaccine production cell line, IC31® adjuvant).
Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great
Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com.
Contacts
Laetitia Bachelot-Fontaine Teresa
Pinzolits
Head of Investor Relations Corporate
Communications
& Corporate Communications T +43-1-206 20-1116
T
+02-28-07-14-19
M +43-676-84 55 67 357
M +33 (0)6 4516
7099 communications@valneva.com
investors@valneva.com
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including
with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the
ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for
future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for
additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future.
In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates,"
"believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the
current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the
expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of
vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency
fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other
proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the
forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these
materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or otherwise.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/f6a3c8ea-e895-49de-ba4a-2c1f70027311
